Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2013) 32 P844 | DOI: 10.1530/endoabs.32.P844

1Instituto de Biomedicina de Sevilla (IBiS), Consejo Superior de Investigaciones Científicas, Endocrinology Unit of Virgen del Rocío University Hospital, University of Seville, Sevilla, Spain; 2Department of Cell Biology, Physiology and Immunology of University of Córdoba, Reina Sofía University Hospital, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), CIBER Fisiopatolog, Córdoba, Spain; 3Endocrinology and Nutrition Unit, Departament of Clinical Medicine, Hospital Universitario de Alicante, Universidad Miguel Hernández, Alicante, Spain; 4Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC), Barcelona, Spain; 5Service of Endocrinology and Nutrition, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Reina Sofía University Hospital, Córdoba, Spain; 6Department of Pathology, Virgen del Rocio University Hospital, Sevilla, Spain; 7Endocrinology/Medicine Departments, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Hospital Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; 8Service of Endocrinology, Hospital de la Ribera, Alzira, Valencia, Spain; 9Endocrinology Department, Complejo Hospitalario Universitario de Santiago de Compostela (SERGAS), Fundación para a Investigación, Desenvolvemento e Innovación Ramón Domínguez (Fundación Ramón Domíngue), Santiago de Compostela, Spain.

Pituitary adenomas are heterogeneous, rare tumors, which hinders analysis of large numbers of cases with common approaches. To overcome this, a multicenter, clinical-basic strategy was proposed aimed at enhancing the tools to diagnose and manage pituitary tumors by combining clinical/pathological/molecular information. This initiative was developed by the Sociedad Andaluza de Endocrinología y Nutrición, and further endorsed by the Sociedad Española de Endocrinología y Nutrición, and supported by Novartis. A comprehensive strategy based on a coordinated network was designed covering all Spanish reference centers for pituitary pathology. To develop a shared database registering clinical, pathological and molecular information for each patient and minimize intercenter variability, common protocols and methods were set up for tissue collection, clinical, pathological and molecular data analysis and registry. This joint initiative, named Spanish molecular registry of pituitary adenomas (REMAH) was established in 2010 and organized in six regional nodes. A common database has been generated ( including clinical and pathological information. A standardized system for adenoma molecular phenotyping was developed and validated. Specifically, 26 genes were evaluated by quantitative real-time PCR, including pituitary hormones, receptors for somatostatin, dopamine, GHRH, GnRH, CRH, vasopressin and ghrelin, plus additional selected markers (Ki-67, PTTG-1) and three housekeeping genes for normalization (β actin, HPRT, and GAPDH). Molecular information was obtained on 250 tumors, out of 634 patients registered until 2012. Initial analysis indicates a close parallelism of the molecular profile of the adenoma subtypes with previously reported data and with the clinical phenotype of the patients, and also provide additional information on specific receptors known as drug-targets. REMAH is a unique, country-wise, multi-centric, multi-disciplinary network of expertise supported on a shared database enabling a translational, more powerful approach to the management of pituitary adenomas, paving the way for innovative clinical-basic studies with large numbers of patients of these rare pathologies.

Article tools

My recent searches

No recent searches.